Evidence mapPaperPMID 36960780Full record

ReviewBriefings in bioinformatics2023

Analysis of super-enhancer using machine learning and its application to medical biology.

Ryuji Hamamoto, Ken Takasawa, Norio Shinkai, Hidenori Machino, Nobuji Kouno, Ken Asada, Masaaki Komatsu, Syuzo Kaneko

Open access · hybridAbstract readReview
In one paragraph

Review in Briefings in bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Enhancer regulation in cancer: from epigenetics to mArchives of pharmacal research · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Machine learning and network analysis with focus on the biofilm inComputational and structural biotechnology journal · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ryuji HamamotoDivision Chief in the Division of Medical AI Research and Development, National Cancer Center Research Institute; a Professor in the Department of NCC Cancer Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University and a Team Leader of the Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project.
Ken TakasawaCancer Translational Research Team, RIKEN Center for Advanced Intelligence Project and an External Research Staff in the Medical AI Research and Development, National Cancer Center Research Institute.
Norio ShinkaiDepartment of NCC Cancer Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Hidenori MachinoCancer Translational Research Team, RIKEN Center for Advanced Intelligence Project and an External Research Staff in the Medical AI Research and Development, National Cancer Center Research Institute.
Nobuji KounoDepartment of Surgery, Graduate School of Medicine, Kyoto University.
Ken AsadaCancer Translational Research Team, RIKEN Center for Advanced Intelligence Project and an External Research Staff of Medical AI Research and Development, National Cancer Center Research Institute.
Masaaki KomatsuCancer Translational Research Team, RIKEN Center for Advanced Intelligence Project and an External Research Staff of Medical AI Research and Development, National Cancer Center Research Institute.
Syuzo KanekoDivision of Medical AI Research and Development, National Cancer Center Research Institute and a Visiting Scientist in the Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project.
RIKEN Center for Advanced Intelligence Project · JPKyoto University · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The analysis of super-enhancers (SEs) has recently attracted attention in elucidating the molecular mechanisms of cancer and other diseases. SEs are genomic structures that strongly induce gene expression and have been reported to contribute to the overexpression of oncogenes. Because the analysis of SEs and integrated analysis with other data are performed using large amounts of genome-wide data, artificial intelligence technology, with machine learning at its core, has recently begun to be utilized. In promoting precision medicine, it is important to consider information from SEs in addition to genomic data; therefore, machine learning technology is expected to be introduced appropriately in terms of building a robust analysis platform with a high generalization performance. In this review, we explain the history and principles of SE, and the results of SE analysis using state-of-the-art machine learning and integrated analysis with other data are presented to provide a comprehensive understanding of the current status of SE analysis in the field of medical biology. Additionally, we compared the accuracy between existing machine learning methods on the benchmark dataset and attempted to explore the kind of data preprocessing and integration work needed to make the existing algorithms work on the benchmark dataset. Furthermore, we discuss the issues and future directions of current SE analysis.

Indexed as

AlgorithmsArtificial IntelligenceEnhancer Elements, GeneticGenomicsMachine LearningChIP-seqhigh-order chromatin structuremachine learningprecision medicinesuper-enhancer

Identifiers

PMID36960780
PMCPMC10199775
OpenAlexW4360804057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.